Category: Science


Clinical Trials to Watch: Turning Cold Tumors Hot

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 15 May 2019 In Science, Treatment

We know that the billions of bacteria that live in our bodies can impact the way we respond to immunotherapy, but can we harness this help more patients respond these life-saving drugs?

Read More


Research is Hope: MRA Announces $8.2 Million for New Grant Awards to Advance Melanoma Research

By Cody R. Barnett, MRA Director of Communications | 30 April 2019 In News, Science

In advance of Melanoma Awareness Month, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced funding for 33 innovative research awards totaling $8.26 million.

Read More


Melanoma Vaccines Show Promise

14 April 2019 In Science, Treatment

While immunotherapy has transformed way melanoma is treated, about half of patients still do not respond. Researchers are pursuing multiple strategies to understand why this happens and to develop strategies to jumpstart a response. One approach showing promise in early clinical trials, comes in the form of new personalized vaccines being developed by Ugur Sahin of Johannes Gutenberg-Universität Mainz and BioNTech.

Read More


What’s Next for the Microbiome in Melanoma?

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 11 April 2019 In Science, Treatment

We know that the billions of bacteria that live in our bodies can impact the way we respond to immunotherapy, but can we harness this help more patients respond these life-saving drugs?

Read More


This Engineer is Building a ‘Better’ Biopsy

By Cody R. Barnett, MRA Director of Communications | 20 March 2019 In Science

Biopsies are an important tool to determine if a mole or other lesion is cancerous. For most patients, the occasional biopsy is no big deal. However for patients facing multiple abnormal or otherwise ‘suspicious’ spots in highly visible places the prospect can be daunting. Dr. Jesse Wilson, an MRA-funded investigator, is an engineer on a mission to build a better biopsy.

Read More


Bronze Bodies and Black Lungs: Five Ways the Tanning and Tobacco Industries Use the Same Playbook

By Charles Brodine, MRA Intern | 17 March 2019 In Prevention, Science

Dr. Alan Blum has crusaded against the tobacco industry for 30 years and now he's taking aim at the tanning industry. According to Blum, both the tobacco and tanning industries exploit people in similar ways, by targeting youth, downplaying their own corporate responsibility, infiltrating pop-culture, and indeed, by becoming prolific icons.

Read More


Fight Back Give Back with Clinical Trials

By Cody R. Barnett, MRA Director of Communications | 24 February 2019 In News, Science

When patients understand all of their options, including clinical trials, they can make informed decisions about their care. For many patients, clinical trials represent the best possible way to get access to cutting-edge treatment options.

Read More


Overcoming Targeted Therapy Resistance

By Marc Hurlbert, Ph.D., MRA Chief Science Officer | 22 February 2019 In Science, Treatment

Targeted therapies work well for many patients, but most will go on to develop acquired resistance. Researchers are working to address this challenge. Learn about two promising examples.

Read More


It’s Not that Simple: Young Women and Melanoma

By Cody R. Barnett, MRA Director of Communications | 15 February 2019 In Prevention, Science

Article after article describes the ‘skyrocketing’ increases in melanoma among young women. While most are quick to point out the clear association between intentional tanning and skin cancer, few ever hint that there may be more to the story.

Read More


Unchartered Territory: When Should Patients Stop Immunotherapy?

By Cody R. Barnett, MRA Director of Communications | 23 January 2019 In Melanoma Stories, Science, Treatment

For melanoma patients, deciding when to discontinue treatment is a difficult decision. should the general ‘rule of thumb’ of treating patients with advanced disease until progression still apply? In the absence of definitive data – what does indirect data tell us?

Read More


Login

×